Artwork

Sisällön tarjoaa Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston. Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!

Episode 23 - Greg Kunst and Corneal Endothelial Therapy for Partial or Full Vision Loss

35:26
 
Jaa
 

Manage episode 422163749 series 3380376
Sisällön tarjoaa Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston. Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

My guest in this episode is Greg Kunst, CEO of Aurion Biotech.

At Aurion, Greg and his colleagues are working on a regenerative treatment (corneal endothelial cell therapy) for millions of people who have partial or complete vision loss.

Greg joined Aurion Biotech with deep and varied experience in ophthalmic medical devices, drug delivery systems, diagnostics, biotechnology, and pharmaceutical products. His expertise spans global corporate development, strategy, health policy, marketing, commercialization, business development, market access and medical affairs.

Before Aurion Biotech, Greg spent 6 years at Glaukos Corporation (NYSE: GKOS) in numerous roles of increasing responsibility, most recently as vice president of global marketing.

Before Glaukos, Greg worked at Alcon, a Novartis company, as global franchise director over the Alcon glaucoma surgery and retina pharmaceutical businesses.

Greg is a board member of Pr3vent. He received an MBA from Vanderbilt University and a BS in Economics from Brigham Young University.

In this interview, Greg talks about why he decided to dedicate his life to eye therapies, the origin of Aurion (Dr. Shigeru Kinoshita's research in Corneal Endothelial Cell Therapy), how he remains positive in spite of being a self-proclaimed news junkie, and his unequivocal commitment to making Aurion therapies affordable for everyone.

I thoroughly enjoyed my chat with Greg. Hope you do too.

  continue reading

27 jaksoa

Artwork
iconJaa
 
Manage episode 422163749 series 3380376
Sisällön tarjoaa Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston. Samir Gondalia, ISPE Boston, Samir Gondalia, and ISPE Boston tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

My guest in this episode is Greg Kunst, CEO of Aurion Biotech.

At Aurion, Greg and his colleagues are working on a regenerative treatment (corneal endothelial cell therapy) for millions of people who have partial or complete vision loss.

Greg joined Aurion Biotech with deep and varied experience in ophthalmic medical devices, drug delivery systems, diagnostics, biotechnology, and pharmaceutical products. His expertise spans global corporate development, strategy, health policy, marketing, commercialization, business development, market access and medical affairs.

Before Aurion Biotech, Greg spent 6 years at Glaukos Corporation (NYSE: GKOS) in numerous roles of increasing responsibility, most recently as vice president of global marketing.

Before Glaukos, Greg worked at Alcon, a Novartis company, as global franchise director over the Alcon glaucoma surgery and retina pharmaceutical businesses.

Greg is a board member of Pr3vent. He received an MBA from Vanderbilt University and a BS in Economics from Brigham Young University.

In this interview, Greg talks about why he decided to dedicate his life to eye therapies, the origin of Aurion (Dr. Shigeru Kinoshita's research in Corneal Endothelial Cell Therapy), how he remains positive in spite of being a self-proclaimed news junkie, and his unequivocal commitment to making Aurion therapies affordable for everyone.

I thoroughly enjoyed my chat with Greg. Hope you do too.

  continue reading

27 jaksoa

Kaikki jaksot

×
 
Loading …

Tervetuloa Player FM:n!

Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.

 

Pikakäyttöopas